Elon Musk’s Neuralink brain chip implanted into two quadriplegic Canadian patients
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $205*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*First annual payment billed as $205.00 + GST for one year. This annual subscription will automatically renew at $233.00 + GST every 52 weeks (10% off the regular annual price of $259.35). Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 05/09/2025 (399 days ago), so information in it may no longer be current.
TORONTO – Two Canadian patients with spinal cord injuries have received Neuralink brain implants that have allowed them to control a computer with their thoughts.
They are part of the first clinical trial outside of the United States to test the safety and effectiveness of Elon Musk’s Neuralink wireless brain chip, which he introduced to the public in 2020, and was first implanted in a paralyzed American in 2024.
The Canadian men, both around 30 years old – one from Ontario, the other from Alberta – have limited or no ability to use their hands.
Dr. Andres Lozano, a neurosurgeon at University Health Network who led the surgical team at Toronto Western Hospital, said the patients could move a computer cursor almost immediately after the surgery. They were able to leave the hospital following their respective procedures on Aug. 27 and Sept. 3 the next morning, he said.
Electrodes were implanted into the motor area of each patient’s brain to harness neuron signals and translate those signals into actions on an external device, skipping over the need to physically move, Lozano explained.
“The first patient was able to control a cursor by just thinking within minutes. It is extremely rapid. The signals are decoded and the artificial intelligence reads the signals and then translates them into movement on the cursor,” he said.
“They just think about it and it happens.”
Brain-computer interface (BCI) devices are not exclusive to Neuralink, and other companies like New-York based Synchron, are conducting their own clinical trials.
The promise of this technology is encouraging, but expectations should be tempered, said Barry Munro, chief development officer of the Canadian Spinal Research Organization.
Munro, who has been quadriplegic since a diving accident 38 years ago, said he has dedicated his life to spinal cord injury research, and helped with recruitment for Neuralink’s U.S. trial. The first person to receive the device last year has said publicly that it started slipping out of his brain weeks after the surgery, setting back his progress, but that he’s since stabilized and that it has still been worthwhile.
Munro said he has witnessed “false hope” time and again in this field and instead encourages “educated hope” — to learn and be excited without expecting an implant like this to be available within the next six months.
“We ain’t there yet, that’s all,” he said.
The Canadian patients will be monitored for at least a year, with the clinical research team permitted to enrol another four patients in the country who have either been paralyzed by a spinal cord injury or who have Amyotrophic Lateral Sclerosis (ALS).
The clinical trial team will be evaluating if the technology is safe and if it adds value to the patient’s quality of life. Side effects they will be looking out for could include seizures, infections or strokes.
In the coming weeks and months, the patients will learn to type on a computer without touching a keyboard. Already, they are able to play video games.
“It’s really as a preliminary step to see whether this should be scaled and rolled out to a larger population,” Lozano said.
“The device right now is a cursor, but in the future you could drive a car, you could drive your wheelchair, you could drive a robot.”
This report by The Canadian Press was first published Sept. 5, 2025.
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
